Bicara Therapeutics Files for IPO

TL;DR

Bicara Therapeutics files S-1 for IPO, aiming to fund its cancer and autoimmune drug pipeline.

AI Summary

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, filed an S-1 registration statement on August 22, 2024, to offer its securities. The company is focused on developing novel therapies for cancer and autoimmune diseases. The filing details its business operations, financial condition, and the proposed terms of its initial public offering, though specific dollar amounts for the offering are not yet detailed in this initial filing.

Why It Matters

This S-1 filing marks Bicara Therapeutics' initial step towards becoming a publicly traded company, potentially providing it with capital to advance its drug pipeline and impacting the competitive landscape in biopharmaceutical innovation.

Risk Assessment

Risk Level: medium — As a clinical-stage biopharmaceutical company, Bicara Therapeutics faces inherent risks associated with drug development, regulatory approvals, and market adoption.

Key Numbers

• 333-281722 — SEC File Number (Identifies the specific SEC registration filing.)
• 20240822 — Filing Date (Date the S-1 registration statement was officially filed with the SEC.)

Key Players & Entities

• Bicara Therapeutics Inc. (company) — Registrant
• Claire Mazumdar (person) — Chief Executive Officer
• Kingsley L. Taft (person) — Counsel for Registration
• Gabriela Morales-Rivera (person) — Counsel for Registration
• Amarilice Young (person) — Counsel for Registration
• Goodwin Procter LLP (company) — Legal Counsel
• Lara Meisner (person) — Chief Legal Officer and Corporate Secretary
• 245 MAIN STREET, CAMBRIDGE, MA 02142 (location) — Principal Business Address
• 116 Huntington Avenue, Suite 703 Boston, MA 02116 (location) — Principal Executive Offices

FAQ

Filing Documents

• d821336ds1.htm (S-1) — 2359KB
• d821336dex31.htm (EX-3.1) — 139KB
• d821336dex33.htm (EX-3.3) — 82KB
• d821336dex42.htm (EX-4.2) — 153KB
• d821336dex101.htm (EX-10.1) — 243KB
• d821336dex105.htm (EX-10.5) — 16KB
• d821336dex106.htm (EX-10.6) — 77KB
• d821336dex108.htm (EX-10.8) — 34KB
• d821336dex109.htm (EX-10.9) — 103KB
• d821336dex1010.htm (EX-10.10) — 248KB
• d821336dex1011.htm (EX-10.11) — 255KB
• d821336dex211.htm (EX-21.1) — 2KB
• d821336dex231.htm (EX-23.1) — 1KB
• d821336dexfilingfees.htm (EX-FILING FEES) — 19KB
• g821336g00a08.jpg (GRAPHIC) — 161KB
• g821336g00q02.jpg (GRAPHIC) — 217KB
• g821336g01r87.jpg (GRAPHIC) — 84KB
• g821336g05g18.jpg (GRAPHIC) — 84KB
• g821336g10k10.jpg (GRAPHIC) — 147KB
• g821336g10r10.jpg (GRAPHIC) — 194KB
• g821336g12w20.jpg (GRAPHIC) — 239KB
• g821336g14t99.jpg (GRAPHIC) — 148KB
• g821336g24l67.jpg (GRAPHIC) — 194KB
• g821336g37a01.jpg (GRAPHIC) — 32KB
• g821336g41g41.jpg (GRAPHIC) — 173KB
• g821336g41j07.jpg (GRAPHIC) — 146KB
• g821336g48g48.jpg (GRAPHIC) — 64KB
• g821336g61i92.jpg (GRAPHIC) — 151KB
• g821336g69p26.jpg (GRAPHIC) — 120KB
• g821336g71t91.jpg (GRAPHIC) — 95KB
• g821336g82t28.jpg (GRAPHIC) — 38KB
• g821336g82t29.jpg (GRAPHIC) — 90KB
• g821336g82t30.jpg (GRAPHIC) — 100KB
• g821336g89p15.jpg (GRAPHIC) — 178KB
• g821336g92o32.jpg (GRAPHIC) — 51KB
• 0001193125-24-205393.txt ( ) — 7406KB

Risk Factors

Risk Factors 13 Special Note Regarding Forward-looking Statements 77

Use Of Proceeds

Use Of Proceeds 79 Dividend Policy 81 Capitalization 82

Managements Discussion and Analysis of Financial Condition and Results

Managements Discussion and Analysis of Financial Condition and Results of Operations 87

Business

Business 103 Management 150

Executive Compensation

Executive Compensation 161 Director Compensation 176 Certain Relationships and Related Party Transactions 179 Principal Stockholders 186

Description of Capital Stock

Description of Capital Stock 190 Shares Eligible For Future Sale 196 Material U.S. Federal Income Tax Considerations for Non-U.S. Holders of Common Stock 198

Underwriting

Underwriting 202 Legal Matters 211 Experts 211 Where You Can Find More Information 211 Index to Financial Statements F-1 Through and including, 2024 (the 25 th day after the date of this prospectus), all dealers effecting transactions in our common stock, whether or not participating in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to a dealers obligation to deliver a prospectus when acting as an underwriter and with respect to an unsold allotment or subscription. Neither we nor the underwriters have authorized anyone to provide any information or make any representations other than those contained in this prospectus or in any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. We and the underwriters are not making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus or in any applicable free writing prospectus is current only as of the date on the front cover of this prospectus, regardless of its time delivery or any sale of shares of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. We own various U.S. federal trademark applications, registered and unregistered trademarks, and trade names including our company name. All other trademarks or trade names referred to in this prospectus are the property of their respective owners. Solely for convenience, the trademarks and trade names in this prospectus are referred to without the symbols ® and , but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. F

View Full Filing

View this S-1 filing on SEC EDGAR